Compare PGEN & AVAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | AVAH |
|---|---|---|
| Founded | 1998 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2013 | 2021 |
| Metric | PGEN | AVAH |
|---|---|---|
| Price | $4.24 | $7.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $8.33 | ★ $9.75 |
| AVG Volume (30 Days) | ★ 3.0M | 1.4M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1850.00 |
| EPS | N/A | ★ 0.19 |
| Revenue | $230,981,000.00 | ★ $2,433,199,000.00 |
| Revenue This Year | $1,115.92 | $7.31 |
| Revenue Next Year | $81.04 | $5.59 |
| P/E Ratio | ★ N/A | $40.37 |
| Revenue Growth | N/A | ★ 20.19 |
| 52 Week Low | $1.28 | $3.73 |
| 52 Week High | $5.47 | $10.32 |
| Indicator | PGEN | AVAH |
|---|---|---|
| Relative Strength Index (RSI) | 52.41 | 57.10 |
| Support Level | $3.97 | $6.18 |
| Resistance Level | $4.40 | $7.52 |
| Average True Range (ATR) | 0.25 | 0.36 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 30.98 | 54.87 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). The Private Duty Services segment generates the majority of revenue, which includes private duty skilled nursing services, non-clinical and personal care services, and pediatric therapy services, and is principally reimbursed by Medicaid and Medicaid MCO.